609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630885757976576 |
|---|---|
| author | Maike Schmidt Sariah Kell Dylan M Glatt Sophia R Majeed |
| author_facet | Maike Schmidt Sariah Kell Dylan M Glatt Sophia R Majeed |
| author_sort | Maike Schmidt |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:13:16Z |
| format | Article |
| id | doaj.art-3cc17f3861054409a4319a0a3b1c160a |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:13:16Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-3cc17f3861054409a4319a0a3b1c160a2023-11-11T08:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0609609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignanciesMaike Schmidt0Sariah Kell1Dylan M Glatt2Sophia R Majeed3323andMe, South San Francisco, CA, USA323andMe, South San Francisco, CA, USA23andMe Inc., South San Francisco, CA, USA23andMe Inc., South San Francisco, CA, USA |
| spellingShingle | Maike Schmidt Sariah Kell Dylan M Glatt Sophia R Majeed 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies Journal for ImmunoTherapy of Cancer |
| title | 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies |
| title_full | 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies |
| title_fullStr | 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies |
| title_full_unstemmed | 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies |
| title_short | 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies |
| title_sort | 609 phase 1 2a dose selection of 23me 00610 a first in class anti cd200r1 antibody in patients with advanced solid malignancies |
| work_keys_str_mv | AT maikeschmidt 609phase12adoseselectionof23me00610afirstinclassanticd200r1antibodyinpatientswithadvancedsolidmalignancies AT sariahkell 609phase12adoseselectionof23me00610afirstinclassanticd200r1antibodyinpatientswithadvancedsolidmalignancies AT dylanmglatt 609phase12adoseselectionof23me00610afirstinclassanticd200r1antibodyinpatientswithadvancedsolidmalignancies AT sophiarmajeed 609phase12adoseselectionof23me00610afirstinclassanticd200r1antibodyinpatientswithadvancedsolidmalignancies |